Elsevier

Biological Psychiatry

Volume 61, Issue 4, 15 February 2007, Pages 551-553
Biological Psychiatry

Brief report
Omega-3 Fatty Acids Supplementation in Children with Autism: A Double-blind Randomized, Placebo-controlled Pilot Study

https://doi.org/10.1016/j.biopsych.2006.05.007Get rights and content

Background

There is increasing evidence that fatty acid deficiencies or imbalances may contribute to childhood neurodevelopmental disorders.

Methods

We conducted a randomized, double-blind, placebo-controlled 6-week pilot trial investigating the effects of 1.5 g/d of omega-3 fatty acids (.84 g/d eicosapentaenoic acid, .7 g/d docosahexaenoic acid) supplementation in 13 children (aged 5 to 17 years) with autistic disorders accompanied by severe tantrums, aggression, or self-injurious behavior. The outcome measure was the Aberrant Behavior Checklist (ABC) at 6 weeks.

Results

We observed an advantage of omega-3 fatty acids compared with placebo for hyperactivity and stereotypy, each with a large effect size. Repeated-measures ANOVA indicated a trend toward superiority of omega-3 fatty acids over placebo for hyperactivity. No clinically relevant adverse effects were elicited in either group.

Conclusions

The results of this study provide preliminary evidence that omega-3 fatty acids may be an effective treatment for children with autism.

Section snippets

Methods and Materials

The study protocol was approved by the institutional review board of the Medical University of Vienna, and written informed consent was obtained from a parent or guardian before enrollment. Study participants were recruited from 22 children and adolescents (mean age ± SD, 10.4 y ± 3.2) attending a specialized day care center for long-term treatment of autistic children; 81.9% were male. Mean length of center attendance at baseline was 7.4 (±3.3) years. All children met the DSM-IV criteria for a

Results

Thirteen (59.1%) of the 22 children who were screened for the intervention study met inclusion criteria for study participation. All of them were males. Those children were randomly assigned to receive either the experimental medication (n = 7) or placebo (n = 6). The mean age (±SD) was 10.5 (±3.2) years in the experimental group and was 12.1 (±2.7) years in the placebo group. One individual from the placebo group withdrew from the trial after 2 weeks because of gastrointestinal complaints and

Discussion

One to 3 g of EPA or up to 10 g/d of fish oil preparations (containing mixtures of EPA and DHA) have been beneficial in a range of disorders including schizophrenia, depression, bipolar disorder, attention-deficit/hyperactivity disorder, dyslexia, and dyspraxia (Richardson 2004). The present findings suggest that omega-3 fatty acids may also be an effective and well-tolerated treatment, in particular of hyperactive behaviors including disobedience, distractibility, and impulsivity, in children

References (21)

There are more references available in the full text version of this article.

Cited by (0)

View full text